INCHEON, Korea – Feb 16, 2025 – Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Ospomyv (denosumab-dssb; SB16; 60 mg pre-filled syringe)…Original Article
FDA Approves Ospomyv (denosumab-dssb), a Biosimilar to Prolia
